AbbVie shares Q3 2026 financial results after stock ends session up 1.7%

AbbVie shares Q3 2026 financial results after stock ends session up 1.7%
AbbVie stock rises 1.7% to $290.97

AbbVie unveiled its Q3 2026 financial results in a company video update. The stock is up 1.7% on the day at $290.97.

ABBV price prediction
24H -0.24%
$282.85
48H -1.37%
$279.65
7D -1.42%
$279.52
1M 3.23%
$292.7
3M 11.62%
$316.5
6M 4.65%
$296.73
12M 26.54%
$358.78
Current price: $283.54 -2.4200 0.85%
Closed 11/19
Daily range 279.96 Arrow from to Icon 285.58
Weekly range 284.94 Arrow from to Icon 301.20
Loading...

Highlights

  • AbbVie reported Q3 2026 financial results, operating with trailing revenue of $64.38 billion and a market value near $488.55 billion.
  • Among 122 analysts, 97 rate AbbVie stock a buy and 4 recommend selling, with the latest $280 price target from RBC Capital.
  • AbbVie stock is up 1.7% on the day at $290.97 and trades at 78 times trailing earnings versus a forward multiple of 17.

AbbVie shared a video highlighting its Q3 2026 financial results, displaying its logo and animated performance graphs. The company is followed by 122 analysts, of whom 97 rate the stock a buy and 4 recommend selling. AbbVie operates in the general drug manufacturing sector, employs around 57,000 people, and holds a market value close to $488.55 billion on trailing revenue of $64.38 billion.

Price holds bullish trend as overbought signals emerge near resistance

AbbVie stock opened the session with a gap up from the prior close, jumping from $285.99 to $291 before retracing some of that initial advance. The underlying trend remains bullish, with price holding above its MA-20, MA-50, and MA-200 levels. Continued strength is suggested by alignment with the broader bullish daily chart structure, but RSI at 67.4 indicates the advance is beginning to look stretched as it moves near overbought territory. The nearest resistance is the weekly high at $292.67.

Upside odds dominate as traders watch for a close above the weekly high

To gauge whether the latest news is being incorporated, traders should watch for a close above the weekly high at $292.67. The stock opened sharply higher, jumping from $285.99 to $291, before pulling back from those early gains. From here, the probability of further upside over the next five trading days is more than 80%, with downside risk less than 20% and an expected trading range from $285.85 to $296.08. A close above the weekly high would indicate buyers are ready to extend the rally, while a drop below $281.23 would suggest the move is losing traction. On the weekly chart, the longer-term picture remains firmly constructive.

Earlier, analysts noted that AbbVie's bullish technical structure persisted as investors anticipated its quarterly results. The latest video update confirming Q3 2026 results adds a new catalyst, with a close above the weekly high at $292.67 now serving as the key level to signal continued upside momentum.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.